^
    1d
    EVICTION: First-in-Human Study of ICT01 in Patients With Advanced Cancer (clinicaltrials.gov)
    P1/2, N=292, Active, not recruiting, ImCheck Therapeutics | Trial completion date: Dec 2025 --> Oct 2026 | Trial primary completion date: Sep 2025 --> Oct 2026
    Trial completion date • Trial primary completion date • Checkpoint inhibition • First-in-human
    |
    Keytruda (pembrolizumab) • ICT01
    1d
    10-year experience of CD22 CAR T-cells for children and young adults with B-cell acute lymphoblastic leukemia. (PubMed, Blood Adv)
    Given the critical importance of CD22 targeting, this experience serves as a foundation for new approaches targeting CD22 while providing ongoing support for dual-targeting approaches and insights into toxicity mitigation. NCT02315612.
    Journal
    |
    CD22 (CD22 Molecule)
    2d
    Widespread remodeling of the RNA editome underlies transcriptional and clinical heterogeneity in pediatric acute lymphoblastic leukemia. (PubMed, bioRxiv)
    Unexpectedly, increased editing levels in select genes ( CD247 , PRKCA and TRAF3IP2.ASI in T-ALL; SPPL3 in B-ALL) were significantly associated with better patient survival, suggesting a potential prognostic role for editing dysregulation at individual gene levels. Together, these results deepen our understanding of the pediatric ALL transcriptome landscape and provided novel candidate regulators and therapeutic targets for future mechanistic and translational investigation.
    Journal
    |
    CD47 (CD47 Molecule) • ADAR (Adenosine Deaminase RNA Specific) • PRKCA (Protein Kinase C Alpha)
    2d
    A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P1/2, N=104, Recruiting, Amgen | Not yet recruiting --> Recruiting
    Enrollment open • Minimal residual disease
    2d
    A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL (clinicaltrials.gov)
    P1/2, N=281, Recruiting, Amgen | Trial primary completion date: Jul 2027 --> Nov 2027
    Trial primary completion date • Minimal residual disease
    2d
    INCB 84344-102: Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors (clinicaltrials.gov)
    P1/2, N=70, Recruiting, Incyte Biosciences International Sàrl | Trial completion date: Jan 2026 --> Feb 2028 | Trial primary completion date: Jan 2026 --> Feb 2028
    Trial completion date • Trial primary completion date
    |
    FLT3 (Fms-related tyrosine kinase 3) • ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • RET (Ret Proto-Oncogene) • FGFR (Fibroblast Growth Factor Receptor) • BLM (BLM RecQ Like Helicase)
    |
    EGFR mutation • KIT mutation • FGFR mutation • RET mutation
    |
    Iclusig (ponatinib)
    2d
    Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant (clinicaltrials.gov)
    P1/2, N=16, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    cyclophosphamide • fludarabine IV
    2d
    High- Fiber/ Low-fat Diet for Prevention of Recurrent Clostridioides Difficile Infection in Oncology (clinicaltrials.gov)
    P=N/A, N=124, Active, not recruiting, University of Colorado, Denver | Recruiting --> Active, not recruiting | Trial completion date: Dec 2025 --> Mar 2026
    Enrollment closed • Trial completion date
    3d
    Transcutaneous Auricular Vagus Nerve Stimulation for Insomnia in Survivors of Childhood Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P=N/A, N=40, Recruiting, St. Jude Children's Research Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    3d
    Clinical Study of LV009 Injection for the Treatment of Hematologic and Lymphoid Malignancies (clinicaltrials.gov)
    P1, N=10, Recruiting, PersonGen BioTherapeutics (Suzhou) Co., Ltd.
    New P1 trial
    3d
    JKART-1: Study of KTE-X19 in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma or Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P2, N=25, Active, not recruiting, Kite, A Gilead Company | Trial primary completion date: Jul 2027 --> Nov 2025
    Trial primary completion date
    |
    cyclophosphamide • fludarabine IV • Tecartus (brexucabtagene autoleucel)
    3d
    A Phase IB Trial of Subcutaneous Blinatumomab in Combination With Revumenib for Patients With KMT2A-rearranged Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P1, N=20, Not yet recruiting, M.D. Anderson Cancer Center
    New P1 trial
    |
    clonoSEQ
    |
    Revuforj (revumenib)